Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVIR NASDAQ:CMPX NASDAQ:IPA NASDAQ:IPSC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVIRAtea Pharmaceuticals$4.86+3.4%$4.59$2.78▼$6.45$388.95M0.31433,492 shs194,576 shsCMPXCompass Therapeutics$2.14-2.3%$2.08$1.61▼$6.88$385.39M0.94.97 million shs1.68 million shsIPAImmunoPrecise Antibodies$2.10+8.5%$2.19$0.43▼$3.25$96.68M0.532.11 million shs1.97 million shsIPSCCentury Therapeutics$2.17+1.9%$2.28$0.44▼$3.04$391.36M1.551.56 million shs602,780 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVIRAtea Pharmaceuticals-0.84%-3.69%+4.68%-20.07%+25.00%CMPXCompass Therapeutics-3.10%-5.60%+7.88%-62.56%-25.00%IPAImmunoPrecise Antibodies0.00%0.00%0.00%0.00%+5.81%IPSCCentury Therapeutics-3.18%-7.79%-5.33%-17.76%+255.06%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVIRAtea Pharmaceuticals$4.86+3.4%$4.59$2.78▼$6.45$388.95M0.31433,492 shs194,576 shsCMPXCompass Therapeutics$2.14-2.3%$2.08$1.61▼$6.88$385.39M0.94.97 million shs1.68 million shsIPAImmunoPrecise Antibodies$2.10+8.5%$2.19$0.43▼$3.25$96.68M0.532.11 million shs1.97 million shsIPSCCentury Therapeutics$2.17+1.9%$2.28$0.44▼$3.04$391.36M1.551.56 million shs602,780 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVIRAtea Pharmaceuticals-0.84%-3.69%+4.68%-20.07%+25.00%CMPXCompass Therapeutics-3.10%-5.60%+7.88%-62.56%-25.00%IPAImmunoPrecise Antibodies0.00%0.00%0.00%0.00%+5.81%IPSCCentury Therapeutics-3.18%-7.79%-5.33%-17.76%+255.06%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVIRAtea Pharmaceuticals 2.50Moderate BuyN/AN/ACMPXCompass Therapeutics 2.87Moderate Buy$12.25472.43% UpsideIPAImmunoPrecise Antibodies 0.00N/AN/AN/AIPSCCentury Therapeutics 2.43Hold$4.75118.89% UpsideCurrent Analyst Ratings BreakdownLatest IPA, AVIR, IPSC, and CMPX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/2/2026IPSCCentury Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/1/2026CMPXCompass Therapeutics LADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$5.006/4/2026CMPXCompass Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform6/1/2026CMPXCompass Therapeutics Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$6.005/27/2026IPSCCentury Therapeutics MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$8.004/28/2026CMPXCompass Therapeutics Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform4/28/2026CMPXCompass Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$13.00 ➝ $7.004/28/2026CMPXCompass Therapeutics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$10.004/27/2026CMPXCompass Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$24.004/27/2026CMPXCompass Therapeutics D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$30.004/21/2026IPSCCentury Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$2.00 ➝ $5.00(Data available from 7/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVIRAtea PharmaceuticalsN/AN/AN/AN/A$3.53 per shareN/ACMPXCompass Therapeutics$850K453.40N/AN/A$1.11 per share1.93IPAImmunoPrecise Antibodies$17.59M5.50N/AN/A$0.37 per share5.66IPSCCentury Therapeutics$109.16M3.59$0.01 per share165.41$1.82 per share1.19Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVIRAtea Pharmaceuticals-$158.35M-$2.11N/AN/AN/AN/A-57.01%-51.49%8/6/2026 (Estimated)CMPXCompass Therapeutics-$66.49M-$0.41N/AN/AN/AN/A-39.75%-35.29%8/10/2026 (Estimated)IPAImmunoPrecise Antibodies-$21.69M-$0.68N/AN/AN/A-122.10%-40.62%-22.19%N/AIPSCCentury Therapeutics-$9.58M-$1.14N/AN/AN/AN/A-49.89%-37.42%8/13/2026 (Estimated)Latest IPA, AVIR, IPSC, and CMPX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/10/2026Q2 2026CMPXCompass Therapeutics-$0.10N/AN/AN/A($0.60) millionN/A8/6/2026Q2 2026AVIRAtea Pharmaceuticals-$0.56N/AN/AN/A$33.03 millionN/A5/13/2026Q1 2026IPSCCentury Therapeutics-$0.15-$0.11+$0.04-$0.11$2.87 millionN/A5/12/2026Q1 2026AVIRAtea Pharmaceuticals-$0.60-$0.57+$0.03-$0.57$22.42 millionN/A5/5/2026Q1 2026CMPXCompass Therapeutics-$0.10-$0.10N/A-$0.10($0.82) millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAVIRAtea PharmaceuticalsN/AN/AN/AN/AN/ACMPXCompass TherapeuticsN/AN/AN/AN/AN/AIPAImmunoPrecise AntibodiesN/AN/AN/AN/AN/AIPSCCentury TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVIRAtea PharmaceuticalsN/A7.897.89CMPXCompass TherapeuticsN/A19.0419.04IPAImmunoPrecise Antibodies0.492.081.85IPSCCentury TherapeuticsN/A10.2510.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVIRAtea Pharmaceuticals86.67%CMPXCompass Therapeutics68.43%IPAImmunoPrecise Antibodies6.70%IPSCCentury Therapeutics50.20%Insider OwnershipCompanyInsider OwnershipAVIRAtea Pharmaceuticals21.60%CMPXCompass Therapeutics18.70%IPAImmunoPrecise Antibodies6.83%IPSCCentury Therapeutics2.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVIRAtea Pharmaceuticals7080.03 million62.74 millionOptionableCMPXCompass Therapeutics20180.09 million146.41 millionNot OptionableIPAImmunoPrecise Antibodies8046.15 million43.00 millionNot OptionableIPSCCentury Therapeutics170180.35 million176.03 millionOptionableIPA, AVIR, IPSC, and CMPX HeadlinesRecent News About These CompaniesCentury Therapeutics (IPSC) to Present CNTY-813 Data at Scientific CongressesJuly 14 at 7:11 AM | insidermonkey.comCentury Therapeutics, Inc. (NASDAQ:IPSC) Given Consensus Recommendation of "Hold" by AnalystsJuly 10, 2026 | americanbankingnews.comCentury: 'Hold' Based On CNTY-101 Pivot And CNTY-813 T1D Curative PotentialJuly 9, 2026 | seekingalpha.comCentury Therapeutics Selected for Oral Presentations of CNTY-813 Preclinical Data at EASD 2026 and Breakthrough T1D® Clinical & Research Congress 2026July 9, 2026 | globenewswire.comHere's Why We're Watching Century Therapeutics' (NASDAQ:IPSC) Cash Burn SituationJune 13, 2026 | finance.yahoo.comCentury Therapeutics (IPSC) Reports Positive Preclinical Results For Diabetes Cell Therapy CNTY-813June 10, 2026 | insidermonkey.comNew CNTY-813 Preclinical Data Demonstrate Durable Glucose Control, Immune Evasion Under Alloimmune Pressure, and Scalable Manufacturing at ADA 2026June 8, 2026 | globenewswire.comMizuho initiates coverage of Century Therapeutics (IPSC) with outperform recommendationMay 28, 2026 | msn.comCorbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of DirectorsMay 14, 2026 | globenewswire.comCentury Therapeutics Reports First Quarter Financial Results and Business UpdatesMay 13, 2026 | globenewswire.comH.C. Wainwright Remains Bullish on Century Therapeutics (IPSC)May 2, 2026 | finance.yahoo.comCentury Therapeutics Selected for Oral Presentation of CNTY‑813 Preclinical Data at the American Diabetes Association 86th Scientific SessionsApril 30, 2026 | globenewswire.com5 Best Performing Small Cap Stocks So Far in 2026April 29, 2026 | insidermonkey.comCentury Therapeutics: A Biotech With Interesting Optionality OpportunitiesApril 24, 2026 | seekingalpha.comCentury Therapeutics Updates ATM Program to Enhance LiquidityMarch 26, 2026 | tipranks.comCentury Therapeutics reports 2025 results, advances cell therapy pipelineMarch 17, 2026 | msn.comDouglas Carr Sells 7,043 Shares of Century Therapeutics (NASDAQ:IPSC) StockMarch 17, 2026 | insidertrades.comCentury Therapeutics (IPSC) Receives a Buy from Clear StreetMarch 14, 2026 | theglobeandmail.comCentury Therapeutics Reports Full Year 2025 Financial Results and Business UpdatesMarch 12, 2026 | markets.businessinsider.comWhy Century Therapeutics, Inc.’s (IPSC) Stock Is Up 5.97%March 6, 2026 | aaii.comANew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesGravity Check: Houston, SpaceX Has a Valuation ProblemBy Jeffrey Neal Johnson | June 16, 20265 Tech Stocks to Buy on the July PullbackBy Thomas Hughes | June 29, 2026The Oil Trade May Not Be Over: 3 Energy Stocks to WatchBy Thomas Hughes | June 21, 2026Could a Tesla-SpaceX Merger Be Closer Than Investors Think?By Sam Quirke | June 17, 2026Is Apple’s Latest Plunge the Canary in the Coal Mine for Tech Stocks?By Sam Quirke | June 29, 2026IPA, AVIR, IPSC, and CMPX Company DescriptionsAtea Pharmaceuticals NASDAQ:AVIR$4.86 +0.16 (+3.40%) Closing price 04:00 PM EasternExtended Trading$4.86 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.Compass Therapeutics NASDAQ:CMPX$2.14 -0.05 (-2.28%) Closing price 04:00 PM EasternExtended Trading$2.16 +0.02 (+1.17%) As of 05:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.ImmunoPrecise Antibodies NASDAQ:IPAImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.Century Therapeutics NASDAQ:IPSC$2.17 +0.04 (+1.88%) Closing price 04:00 PM EasternExtended Trading$2.15 -0.02 (-0.74%) As of 05:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Johnson & Johnson’s Earnings Dip Looks Like a Buying Opportunity Apple’s AI Toll Booth Thesis Faces Its Biggest Test Yet Before Earnings Why ASML’s AI Monopoly Is Still Getting Stronger Alphabet’s AI Spending Question Looms Over Q2 Earnings CPI Comes In Cool: Why It Could Revive These 3 Rate-Sensitive Stocks 2 Quantum Stocks That Could Challenge IonQ’s Leadership 3 Small-Cap Stocks Trading Under $10 With Room to Run Plot Twist: 12 States Could Stall the Paramount-Warner Bros. Discovery Mega-Merger Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
